What is autoimmune hypophysitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Autoimmune Hypophysitis?

Autoimmune hypophysitis is an inflammatory condition of the pituitary gland caused by immune-mediated attack, resulting in pituitary enlargement and varying degrees of hypopituitarism (hormone deficiencies). 1, 2

Definition and Pathophysiology

Autoimmune hypophysitis, also called lymphocytic hypophysitis, occurs when inflammatory cells infiltrate the pituitary tissue, leading to:

  • Initial pituitary enlargement from infiltration and edema
  • Progressive destruction of hormone-producing cells
  • Eventual gland atrophy with fibrotic replacement
  • Various degrees of permanent pituitary dysfunction 3

The autoimmune process is evidenced by circulating antipituitary antibodies (APA), though these have low diagnostic sensitivity and specificity, limiting their clinical utility. Target autoantigens include alpha-enolase, gamma-enolase, pituitary gland specific factors (PGSF) 1 and 2, and TPIT 3.

Clinical Presentation

Primary Autoimmune Hypophysitis

The classic form predominantly affects women (6:1 ratio for anterior pituitary involvement), with 57% of cases presenting during pregnancy or postpartum 4. It has a prevalence of approximately 5 per million and represents 0.5% of hypopituitarism cases and 2% of nonfunctioning pituitary macroadenomas 4.

Common symptoms include:

  • Headache (85% of cases)
  • Fatigue (66% of cases)
  • Visual disturbances (less common) 5

Immunotherapy-Induced Hypophysitis

With immune checkpoint inhibitors (particularly anti-CTLA-4 antibodies like ipilimumab), hypophysitis has become increasingly recognized 5, 6:

  • Incidence: ≤10% with ipilimumab 3 mg/kg, up to 17% at 10 mg/kg
  • Incidence: ≤13% with combination ipilimumab/nivolumab
  • Median onset: 8-9 weeks after starting treatment (typically after third dose) 5

Hormonal Deficiency Pattern

The characteristic pattern differs from typical pituitary tumors 5:

  • Central hypothyroidism (>90% of cases) - most common
  • Central adrenal insufficiency (>75% of cases)
  • Hypogonadotropic hypogonadism
  • Approximately 50% present with panhypopituitarism (all three deficiencies)
  • Prolactin deficiency or paradoxical hyperprolactinemia may occur

Biochemical hallmark: Low TSH with low free T4 (central pattern), distinguishing it from primary thyroid disease 5.

Imaging Characteristics

MRI findings that distinguish hypophysitis from pituitary adenomas 5, 4:

  • Symmetrical and homogeneous enlargement
  • Thickened but undisplaced pituitary stalk
  • Suprasellar convexity
  • Heterogeneous enhancement
  • Increased gland height compared to baseline

Important: Pituitary enlargement can precede clinical symptoms and typically resolves within 2 months, though hormonal deficiencies often persist 5.

Associated Conditions

18% of patients have concurrent autoimmune diseases 4, most commonly:

  • Hashimoto's thyroiditis (most frequent association)
  • Systemic lupus erythematosus
  • IgG4-related disease
  • Rheumatoid arthritis (rare) 7

Diagnostic Approach

Definitive diagnosis requires pituitary biopsy, but a presumptive diagnosis can be made based on 5, 4:

Proposed diagnostic criteria:

  • ≥1 pituitary hormone deficiency (TSH or ACTH deficiency required) + MRI abnormality, OR
  • ≥2 pituitary hormone deficiencies (TSH or ACTH deficiency required) + headache/symptoms

Critical caveat: Biopsy is not always clinically necessary for management and should be reserved for cases where diagnosis significantly impacts treatment decisions or when mass effect requires surgical decompression 4, 8.

Clinical Subtypes

Three anatomical patterns exist 4:

  1. Anterior pituitary alone (65%) - 6:1 female predominance
  2. Anterior and posterior pituitary (25%) - 2:1 female predominance
  3. Neurohypophysis alone (10%) - equal sex distribution

Long-term Implications

Most patients require lifelong hormone replacement 5:

  • Adrenal insufficiency and hypothyroidism typically permanent
  • Only 15/92 patients in one systematic review achieved full pituitary function recovery 9
  • All patients with adrenal insufficiency must carry medical alert identification 5

Critical management principle: When both adrenal insufficiency and hypothyroidism are present, always start steroids before thyroid hormone replacement to avoid precipitating adrenal crisis 5.

References

Research

Autoimmune hypophysitis: new developments.

Handbook of clinical neurology, 2014

Research

Autoimmune hypophysitis.

Endocrine reviews, 2005

Research

Hypophysitis.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.